The impact on pharmaceutical spending derived from the access of biological medicines to the market is significant and growing. Its unquestionable clinical value in increasing the hope and quality of life of many patients is accompanied by a price that is usually higher than that of chemically synthesized drugs. In Europe, biological treatments accounted for around 2018% of all pharmaceutical spending in 30, and this percentage is expected to continue to increase.